Biosimilar BI 695501 Demonstrates Non-Inferior Efficacy and Comparable Safety to Adalimumab Reference Product in Patients With Active Crohn's Disease-MedSci.cn

Biosimilar BI 695501 Demonstrates Non-Inferior Efficacy and Comparable Safety to Adalimumab Reference Product in Patients With Active Crohn's Disease

Hanauer, S; Schreiber, S; Balser, S; Liedert, B

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019; 114 (): S13

科室
- - 订阅+
  - 更多科室
工具
服务